Intellipharmaceutics International Inc. (IPCI)

[Tekterra]

We knew this would happen all along. FDA will pull all none abuse resistant products off the market. This really changed the market shares, and it just makes Rexista that much more valuable assuming it gets through FDA smoothly with proper abuse deterrent labeling.

I guess Endo may do a deal with IPCI then due to PAR relationship with IPCI. This means successful approval year end may see a deal announced with Endo.